A Study of Setmelanotide in Patients With Prader-Willi Syndrome

Summary

This is a Phase 2, open-label study designed to assess the safety and efficacy of setmelanotide in patients with obesity due to Prader-Willi Syndrome (PWS) who are 6 to 65 years of age. Up to 20 patients are planned to be enrolled. Patients will take a daily subcutaneous dose of open-label setmelanotide for up to 52 weeks.

Timeline

Start

2025-03-04

Primary completion

2026-10-31

Completion

2027-10-31

Drugs

Indications